T YPE 1 DIABETES IS a multigenic autoimmune disease
with four loci identified so far, i.e. the major histocompatibility complex on chromosome 6q21 (1), the insulin gene on chromosome 11p15 (2) , the cytotoxic T lymphocyteassociated antigen 4 (CTLA4) locus on chromosome 2q33 (3) , and the protein tyrosine phosphatase nonreceptor type 22 (PTPN22) locus on chromosome 1p13 (4) . Besides major histocompatibility complex, the CTLA4 and PTPN22 have been implicated in multiple autoimmune disorders including autoimmune thyroid disease (AITD), rheumatoid arthritis (RA), systemic lupus erythematosus, and Addison's disease (3, (5) (6) (7) (8) (9) (10) (11) (12) . Recently, linkage and single nucleotide polymorphism (SNP)-based fine mapping studies of type 1 diabetes cohorts narrowed the interval for the IDDM5 locus on chromosome 6q25 to an approximately 200-kb region containing only two genes, SUMO4 and TAB2 (also known as MAP3K7IP2) (13, 14) . Subsequently, a missense polymorphism (rs237025, 163AϾG) that results in a nonconserved substitution of methionine to valine (M55V) within the CUE domain of SUMO4 was proposed as the causative variant of IDDM5 that associated with type 1 diabetes (13, 14) . Functional studies revealed that SUMO4 sumoylates IB␣, acting as a negative feedback regulator for nuclear factor B (NF-B) activity which has a central role in the immune response (14, 15) . The M55V substitution of SUMO4 results in a significant reduction of its sumoylation capacity (14, 16) , leading to higher NF-B activity and enhanced IL-12p40 secretion (14) .
Because a study investigating the shared autoimmunity gene hypothesis has demonstrated linkage and association of the IDDM5 locus with RA (17) and the NF-B regulates a wide variety of immune responses, the SUMO4 could be an important determinant of multiple autoimmune disorders. This prompted us to study the association of the M55V variant in SUMO4 with other autoimmune diseases, including AITD, RA, and primary Sjö gren's syndrome, in addition to type 1 diabetes. We also examined the putative correlation between the SUMO4 genotype and the clinically or genetically defined subset of type 1 diabetes.
Subjects and Methods Subjects
A case-control study was performed to assess associations of the SUMO4 M55V SNP (rs237025, 163AϾG) with type 1 diabetes, AITD, RA, and primary Sjö gren's syndrome. A total of 1480 subjects of Japanese origin, including 929 cases and 551 control subjects, were studied. Cases consisted of 411 patients with type 1 diabetes, 292 AITD, 172 RA, and 54 primary Sjö gren's syndrome. The DNA samples from patients with type 1 diabetes and control subjects were obtained from three of four centers (Osaka, Saitama, and Nagasaki) in the previous study (18), and more than 90% of samples were overlapped. The remaining cases were recruited from the Saitama and Nagasaki area. The clinical characteristics of the subjects are shown in Table 1 . The clinical data on AITD were available in 281 patients with type 1 diabetes.
The diagnosis of type 1 diabetes was made by endocrinologists according to the criteria of National Diabetes Data Group (19). Among the patients with type 1 diabetes, 110 patients (26.7%) were complicated with AITD. AITD consisted of Graves' disease and Hashimoto's thyroiditis and was diagnosed based on the finding of palpable goiter or the presence of chronic thyroiditis with ultrasonography examination in the absence of goiter, abnormal levels of thyroid hormones, and positivity for autoantibodies to thyroid peroxidase (TPO), thyroglobulin (TG), and/or TSH receptor.
Cases with RA and primary Sjö gren's syndrome were assessed by a rheumatologist and fulfilled the American College of Rheumatology (formerly, the American Rheumatism Association) classification criteria for the respective diseases (20). All patients with primary Sjö gren's syndrome, including those without anti-SSA/Ro or anti-SSB/La antibodies, had positive results on lip biopsies, with Daniels' focus scores of more than 2. Amyloidosis was diagnosed based on the presence of Congo red staining and greenish birefringence on polarizing light microscopy of tissue biopsy samples (either sc fat aspiration biopsy, rectal biopsy, gingival/tongue biopsy, or renal biopsy).
The healthy control subjects had no clinical diabetes and no family history of autoimmune diseases. All cases and control subjects were informed of the purpose of the study, and their consent was obtained. The ethics committee from each institute approved the study.
Genotyping and sequencing
Genotyping of SUMO4 M55V was undertaken using TaqMan (Applied Biosystems, Tokyo, Japan) with probes and primers described in previous reports (18, 21). The assay validity was reproduced by PCRrestriction fragment length polymorphism methods with a second nonpolymorphic cutting site in the same PCR products using restriction enzyme TspRI (New England Biolabs, Ipswich, MA) that cleaved the PCR product in the presence of the Valine encoding allele, and a part of them was confirmed by direct sequencing using an ABI 3100 capillary sequencer. No discrepancy was observed between the three methods. Furthermore, no deviations from Hardy-Weinberg equilibrium were observed for SUMO4 M55V AϾG genotypes in control subjects.
The interaction analyses used HLA-DRB1 and two SNPs in the CTLA4, ϩ6230GϾA (CT60, rs3087243) and ϩ49GϾA (rs231775), which were also genotyped as reported previously (22). The data on HLA-DRB1, CTLA4 ϩ6230GϾA, and CTLA4 ϩ49GϾA polymorphism were available in 400, 409, and 405 patients with type 1 diabetes, respectively.
Autoantibody determinations
Antiislet autoantibodies, including anti-GAD antibody and ICA512/ IA-2 antibody, were determined using RIA as described previously (23, 24). Autoantibodies to TPO and TG were measured using a commercial RIA kit, following the instructions provided by the manufacturer (RSR Limited, Cardiff, UK). The cutoff level for TPO antibodies and TG antibodies was 0.2 and 0.3 U/ml, respectively. TSH receptor autoantibody status was determined by a radioactive inhibition method (RSR Limited). Rheumatoid factor was detected by a latex immunoturbidimetric assay with cutoff value of 14 IU/ml (Dade-Behring, Tokyo, Japan). Anti-SSA/Ro and anti-SSB/La antibodies of IgG isotype were measured by an ELISA using a cutoff value of 20 IU/ml or less as suggested by the manufacturer (MBL, Nagoya, Japan).
Statistical analysis
Data are given as mean Ϯ sd. Allelic and genotypic frequencies of all the genetic variants were obtained by direct counting. Deviations from Hardy-Weinberg equilibrium were tested by comparison of observed and expected genotype frequencies. The significance of differences in the distribution of alleles and genotypes between cases and healthy control subjects was determined by 2 method with 2 ϫ 2 contingency tables. Odds ratio (OR) and its 95% confidence interval (95% CI) were also calculated. Statistical heterogeneity between subpopulations was evaluated with the I 2 statistic (25). Statistical tests were considered significant at P value less than 0.05 or, in case of k independent tests, at P value less than 0.05/k (Bonferroni correction).
Results

SUMO4 M55V variant and type 1 diabetes
The patients with type 1 diabetes and healthy control subjects were recruited from three geographical areas in Japan: Osaka, Saitama, and Nagasaki. Similar allele and genotype frequencies were observed in each geographical area and no heterogeneity was found (I 2 ϭ 0.0%). As shown in Tables 2 and 3 , the frequency of subjects with the G allele (encoding Val 55 ) was significantly higher in patients with type 1 diabetes than that in healthy controls [GGϩGA: 58.6 vs. 49.9%, OR: 1.42 (95% CI 1.09 -1.84), P ϭ 0.0072]. We then further analyzed the contributions of (Table 2 ). However, we failed to detect any association between SUMO4 M55V variant and sex, age at disease onset, or presence of antiislet autoantibodies (data not shown). Because of the well-known contribution of IDDM1 in the HLA region and IDDM12 to susceptibility to type 1 diabetes, associations between SUMO4 M55V variant and HLA-DRB1 and CTLA4 were examined. In the Japanese population, HLA-DRB1*0405 and DRB1*0901 confer genetic susceptibility to type 1 diabetes. The frequency of SUMO4 GGϩGA genotype was significantly higher in patients who have neither DRB1*0405 nor DRB1*0901 than that in control subjects [69.4 vs. 49.9%, OR: 2.28 (95% CI 1.34 -3.87), P ϭ 0.0018] or in patients carrying either DRB1 allele [69.4 vs. 56.4%, OR: 1.76 (95% CI 1.02-3.04), P ϭ 0.042; Table 2 ]. Stratification of patients by high-risk (GG) and low-risk (GAϩAA) genotypes of CTLA4 ϩ6230GϾA or ϩ49GϾA showed no difference in the association of SUMO4 GGϩGA genotypes with type 1 diabetes (58.4 vs. 59.6%, OR: 1.05 for ϩ6230GϾA; 57.8 vs. 59.9%, OR: 1.10 for ϩ49GϾA; Table 2 ).
SUMO4 M55V variant and AITD, RA, or primary Sjögren's syndrome
As autoimmune disorders share a number of characteristics and constitute a tendency toward familial aggregation, it is likely that common underlying genes and alleles are involved in some disorders, as demonstrated at CTLA4 or PTPN22. Owing to the accumulating lines of evidence that indicate involvement of the NF-B pathway in the development of autoimmune disorders in humans and mice (26), the SUMO4 M55V variant could be a shared determinant among different autoimmune diseases. Hence, we investigated whether this locus is also associated with AITD, RA, or primary Sjö gren's syndrome. As shown in Tables 4 and 5 RA patients without amyloidosis (OR: 0.97, P ϭ 0.95). No statistically significant differences were observed in the distribution of the SUMO4 genotypes between patients with primary Sjö gren's syndrome and healthy controls. Similarly, no association was detected when patients were stratified according to anti-SSA/Ro and/or anti-SSB/La status (data not shown).
Discussion
The transcription factor NF-B plays a central regulatory role in the immune system, namely, 1) inhibition of immune cell apoptosis, 2) the development of immune cells, 3) the maintenance of immune homeostasis and control of lymphoid architecture, and 4) the regulation of innate and adaptive immune system (27). NF-B is expressed in the cytoplasm of various cell types including lymphocyte, dendritic cells, monocytes/macrophages, granulocytes, and is involved in the development of autoimmune disorders, including type 1 diabetes and RA (28, 29). NF-B activity is negatively regulated by the IB proteins, one of the substrates for SUMO4 sumoylation (15) . Therefore, sumoylation is considered to be a novel negative regulatory mechanism for the control of NF-B transcription activity.
In the present study, we found evidence that type 1 diabetes-associated SUMO4 G allele at position 163 was also associated with an increased risk of AITD and RA, indicating that this locus may have a general effect on predisposition to autoimmunity. Because the involvement of SUMO4 on the regulation of immune function is not limited to the specific organs (30), the current observation showing the much stronger association between SUMO4 M55V variant and type 1 diabetes with AITD is consistent with this hypothesis. Recently, no evidence of association of the SUMO4 M55V SNP with susceptibility to RA, Addison's disease, and Graves' disease was reported in Caucasian populations of European descent (31, 32). Such discrepant associations have also been reported for type 1 diabetes (14, 18, 21, (33) (34) (35) , suggesting that the discrepancies may be caused by genetic heterogeneity or population differences in gene-gene and gene-environmental interactions.
Because genetic interactions between HLA and non-HLA loci have been described in susceptibility for type 1 diabetes and other autoimmune diseases (36 -38), we compared genotype distributions for M55V variant among type 1 diabetes stratified by the presence of high-risk HLA-DRB1 alleles, DRB1*0405 or DRB1*0901, or CTLA4 ϩ6230GG or ϩ49GG genotype. The SUMO4 M55V was associated with type 1 diabetic patients without high-risk HLA-DRB1. This suggests that the SUMO4 M55V might be a supplementary risk factor to type 1 diabetes in patients without susceptible class II HLA haplotypes. However, polymorphisms in the CTLA4, which is also a negative regulator of NF-B activity (39), did not alter the association of SUMO4 with type 1 diabetes, suggesting that SUMO4 M55V and CTLA4 polymorphisms independently contribute to pathogenesis of type 1 diabetes.
In conclusion, the present study indicated that SUMO4 locus within the IDDM5 region contributes to susceptibility to AITD and RA, in addition to type 1 diabetes, and therefore, may be a general autoimmunity gene. It will be interesting to test in future experiments whether M55V is the only autoimmune disease-associated variant in the gene and in this chromosome region. 
